Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises, Inc. (NYSE: NUS) today announced the appointment of Chelsea Lantz as interim Chief Financial Officer, effective immediately. The appointment of Lantz comes after James Thomas stepped down as CFO to pursue an outside opportunity. “On behalf of our board, management and the entire Nu Skin team, we thank James for his leadership and significant contributions over 16 years at Nu Skin and wish him and his family well in their future pursuits,” said.

Top ten large cap value (GASV) stocks are forecasted to deliver an average 38.12% net gain by mid-March 2027, with yields up to 13.03%. Analyst targets suggest the five lowest-priced, highest-yield GASV stocks could outperform, offering an 18.5% higher gain than the top ten as a group. Fourteen of twenty-nine 'safer' lowest-priced GASV stocks are currently buyable, with seven meeting the ideal dividend-to-price criteria for fair value.

PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises Inc. (NYSE:NUS) today announced the appointment of Chayce Clark as chief operating officer effective immediately. Clark will be responsible for leading the company's revenue performance and end-to-end operational execution across the business in addition to maintaining his role as the company's chief legal officer. “Chayce has been a valuable part of our executive team and an important voice in our efforts to become the world's leading intellige.

March's Large Cap Value (GASV) screen highlights 14 fair-priced, 'safer' dividend stocks, including Hafnia Ltd, IRSA Inversiones, and Weibo Corp, as actionable buys. Top ten GASV stocks are projected to deliver an average 33.21% net gain by March 2027, with risk/volatility slightly below the market average. Analyst targets indicate the five lowest-priced, highest-yield GASV stocks could outperform, with Hafnia Ltd showing a potential 42.88% gain.

Nu Skin Enterprises trades at a deep value multiple (~3x 2026 EBITDA) but faces persistent core business decline and unproven turnaround catalysts. Guidance disappointed, yet management expects margin expansion and a return to revenue growth by late 2026, with India and Prysm iO launches as key potential drivers. Non-core assets and a net cash-positive balance sheet provide some downside protection, but secular decline in legacy markets remains a major overhang.

Nu Skin is rated a buy, trading at low multiples with turnaround prospects tied to India expansion and Prysm iO device launch. NUS's core MLM business faces structural decline, but new product and market initiatives could stabilize or grow revenue beyond 2026. Prysm iO potential subscription fees may provide incremental revenue not fully reflected in current guidance.

NUS' fourth-quarter earnings and sales miss estimates, with revenues down 16.9% Y/Y and broad declines across key global regions.